Nantahala Capital Management, LLC Silverback Therapeutics, Inc. Transaction History

Nantahala Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	N/A	497,429 Added 45.26%	1,596,504 $0
Q3 2023 Nov 14, 2023	BUY	N/A	918,978 Added 510.27%	1,099,075 $0
Q2 2023 Aug 14, 2023	BUY	N/A	180,097 New	180,097 $0
Q3 2022 Nov 10, 2022	SELL	$3.91 - $5.52 $532,835 - $752,238	-136,275 Reduced 9.83%	1,249,863 $6.6 Million
Q2 2022 Aug 15, 2022	BUY	$2.9 - $4.44 $1.37 Million - $2.1 Million	472,541 Added 51.72%	1,386,138 $5.88 Million
Q1 2022 May 13, 2022	SELL	$3.51 - $6.74 $325,956 - $625,910	-92,865 Reduced 9.23%	913,597 $3.15 Million
Q4 2021 Feb 14, 2022	SELL	$6.03 - $11.67 $1.33 Million - $2.57 Million	-220,169 Reduced 17.95%	1,006,462 $6.7 Million
Q3 2021 Nov 15, 2021	SELL	$9.98 - $35.22 $395,557 - $1.4 Million	-39,635 Reduced 3.13%	1,226,631 $12.2 Million
Q2 2021 Aug 16, 2021	BUY	$24.71 - $44.28 $6.77 Million - $12.1 Million	274,024 Added 27.62%	1,266,266 $39.1 Million
Q1 2021 May 14, 2021	SELL	$37.62 - $60.41 $8.06 Million - $12.9 Million	-214,229 Reduced 17.76%	992,242 $42.7 Million
Q4 2020 Feb 16, 2021	BUY	$25.0 - $46.34 $30.2 Million - $55.9 Million	1,206,471 New	1,206,471 $54.4 Million

165

62.7M

872K

589K

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nantahala Capital Management, LLC with notifications on news.